Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
50
ADOCY Quote, Financials, Valuation and Earnings
Last price:
$11.80
Seasonality move
:
10.63%
Day range:
$11.80 - $11.80
52-week range:
$11.80 - $11.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
17.36x
P/B ratio:
--
Volume:
--
Avg. volume:
--
1-year change:
--
Market cap:
$231.1M
Revenue:
$10.1M
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ADOCY
Adocia SA
|
-- | -- | -- | -- | -- |
|
CLLS
Cellectis SA
|
$10.6M | -$0.18 | -0.54% | -56.58% | $7.25 |
|
DBVT
DBV Technologies SA
|
$944.7K | -$0.14 | -- | -89.45% | $39.89 |
|
IPHA
Innate Pharma SA
|
$2.7M | -- | -- | -- | $6.00 |
|
NICXF
Nicox SA
|
-- | -- | -- | -- | -- |
|
TRGNF
Transgene SA
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ADOCY
Adocia SA
|
$11.80 | -- | $231.1M | -- | $0.00 | 0% | 17.36x |
|
CLLS
Cellectis SA
|
$3.41 | $7.25 | $354.2M | -- | $0.00 | 0% | 4.85x |
|
DBVT
DBV Technologies SA
|
$21.06 | $39.89 | $1.2B | -- | $0.00 | 0% | -- |
|
IPHA
Innate Pharma SA
|
$1.37 | $6.00 | $130.3M | -- | $0.00 | 0% | 37.39x |
|
NICXF
Nicox SA
|
$0.30 | -- | $24.3M | -- | $0.00 | 0% | 5.89x |
|
TRGNF
Transgene SA
|
$1.00 | -- | $132.3M | -- | $0.00 | 0% | 865.90x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ADOCY
Adocia SA
|
-493.39% | 0.000 | -- | 0.97x |
|
CLLS
Cellectis SA
|
61.24% | 0.555 | 24.69% | 1.53x |
|
DBVT
DBV Technologies SA
|
11.39% | -0.562 | 2.4% | 3.35x |
|
IPHA
Innate Pharma SA
|
55.22% | 0.612 | -- | 2.76x |
|
NICXF
Nicox SA
|
54.24% | 0.170 | 91.41% | 1.21x |
|
TRGNF
Transgene SA
|
-- | 0.607 | -- | 1.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ADOCY
Adocia SA
|
-- | -- | -- | -- | -- | -- |
|
CLLS
Cellectis SA
|
$5.3M | -$18.8M | -31.08% | -65.19% | -181.22% | -$11M |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$45.7M | -176.3% | -217.87% | -- | -$35.6M |
|
IPHA
Innate Pharma SA
|
-- | -- | -39.78% | -72.79% | -- | -- |
|
NICXF
Nicox SA
|
-- | -- | -24.01% | -43.13% | -- | -- |
|
TRGNF
Transgene SA
|
-- | -- | -182.92% | -182.92% | -- | -- |
Adocia SA vs. Competitors
-
Which has Higher Returns ADOCY or CLLS?
Cellectis SA has a net margin of -- compared to Adocia SA's net margin of -253.13%. Adocia SA's return on equity of -- beat Cellectis SA's return on equity of -65.19%.
Company Gross Margin Earnings Per Share Invested Capital ADOCYAdocia SA-- -- -$1.3M CLLSCellectis SA50.92% -$0.26 $195.8M -
What do Analysts Say About ADOCY or CLLS?
Adocia SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Cellectis SA has an analysts' consensus of $7.25 which suggests that it could grow by 112.61%. Given that Cellectis SA has higher upside potential than Adocia SA, analysts believe Cellectis SA is more attractive than Adocia SA.
Company Buy Ratings Hold Ratings Sell Ratings ADOCYAdocia SA0 0 0 CLLSCellectis SA2 2 0 -
Is ADOCY or CLLS More Risky?
Adocia SA has a beta of -0.180, which suggesting that the stock is 118.026% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.907, suggesting its more volatile than the S&P 500 by 190.653%.
-
Which is a Better Dividend Stock ADOCY or CLLS?
Adocia SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adocia SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADOCY or CLLS?
Adocia SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $10.4M. Adocia SA's net income of -- is lower than Cellectis SA's net income of -$26.3M. Notably, Adocia SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adocia SA is 17.36x versus 4.85x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADOCYAdocia SA17.36x -- -- -- CLLSCellectis SA4.85x -- $10.4M -$26.3M
-
Which has Higher Returns ADOCY or DBVT?
DBV Technologies SA has a net margin of -- compared to Adocia SA's net margin of --. Adocia SA's return on equity of -- beat DBV Technologies SA's return on equity of -217.87%.
Company Gross Margin Earnings Per Share Invested Capital ADOCYAdocia SA-- -- -$1.3M DBVTDBV Technologies SA-- -$1.17 $190.5M -
What do Analysts Say About ADOCY or DBVT?
Adocia SA has a consensus price target of --, signalling downside risk potential of --. On the other hand DBV Technologies SA has an analysts' consensus of $39.89 which suggests that it could grow by 89.39%. Given that DBV Technologies SA has higher upside potential than Adocia SA, analysts believe DBV Technologies SA is more attractive than Adocia SA.
Company Buy Ratings Hold Ratings Sell Ratings ADOCYAdocia SA0 0 0 DBVTDBV Technologies SA4 0 1 -
Is ADOCY or DBVT More Risky?
Adocia SA has a beta of -0.180, which suggesting that the stock is 118.026% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.942, suggesting its less volatile than the S&P 500 by 194.186%.
-
Which is a Better Dividend Stock ADOCY or DBVT?
Adocia SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adocia SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADOCY or DBVT?
Adocia SA quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Adocia SA's net income of -- is lower than DBV Technologies SA's net income of -$44.8M. Notably, Adocia SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adocia SA is 17.36x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADOCYAdocia SA17.36x -- -- -- DBVTDBV Technologies SA-- -- -- -$44.8M
-
Which has Higher Returns ADOCY or IPHA?
Innate Pharma SA has a net margin of -- compared to Adocia SA's net margin of --. Adocia SA's return on equity of -- beat Innate Pharma SA's return on equity of -72.79%.
Company Gross Margin Earnings Per Share Invested Capital ADOCYAdocia SA-- -- -$1.3M IPHAInnate Pharma SA-- -- $68.9M -
What do Analysts Say About ADOCY or IPHA?
Adocia SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Innate Pharma SA has an analysts' consensus of $6.00 which suggests that it could grow by 337.96%. Given that Innate Pharma SA has higher upside potential than Adocia SA, analysts believe Innate Pharma SA is more attractive than Adocia SA.
Company Buy Ratings Hold Ratings Sell Ratings ADOCYAdocia SA0 0 0 IPHAInnate Pharma SA3 1 0 -
Is ADOCY or IPHA More Risky?
Adocia SA has a beta of -0.180, which suggesting that the stock is 118.026% less volatile than S&P 500. In comparison Innate Pharma SA has a beta of 0.127, suggesting its less volatile than the S&P 500 by 87.338%.
-
Which is a Better Dividend Stock ADOCY or IPHA?
Adocia SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adocia SA pays -- of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADOCY or IPHA?
Adocia SA quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. Adocia SA's net income of -- is lower than Innate Pharma SA's net income of --. Notably, Adocia SA's price-to-earnings ratio is -- while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adocia SA is 17.36x versus 37.39x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADOCYAdocia SA17.36x -- -- -- IPHAInnate Pharma SA37.39x -- -- --
-
Which has Higher Returns ADOCY or NICXF?
Nicox SA has a net margin of -- compared to Adocia SA's net margin of --. Adocia SA's return on equity of -- beat Nicox SA's return on equity of -43.13%.
Company Gross Margin Earnings Per Share Invested Capital ADOCYAdocia SA-- -- -$1.3M NICXFNicox SA-- -- $46.8M -
What do Analysts Say About ADOCY or NICXF?
Adocia SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Nicox SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Adocia SA has higher upside potential than Nicox SA, analysts believe Adocia SA is more attractive than Nicox SA.
Company Buy Ratings Hold Ratings Sell Ratings ADOCYAdocia SA0 0 0 NICXFNicox SA0 0 0 -
Is ADOCY or NICXF More Risky?
Adocia SA has a beta of -0.180, which suggesting that the stock is 118.026% less volatile than S&P 500. In comparison Nicox SA has a beta of -0.080, suggesting its less volatile than the S&P 500 by 107.966%.
-
Which is a Better Dividend Stock ADOCY or NICXF?
Adocia SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nicox SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adocia SA pays -- of its earnings as a dividend. Nicox SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADOCY or NICXF?
Adocia SA quarterly revenues are --, which are smaller than Nicox SA quarterly revenues of --. Adocia SA's net income of -- is lower than Nicox SA's net income of --. Notably, Adocia SA's price-to-earnings ratio is -- while Nicox SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adocia SA is 17.36x versus 5.89x for Nicox SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADOCYAdocia SA17.36x -- -- -- NICXFNicox SA5.89x -- -- --
-
Which has Higher Returns ADOCY or TRGNF?
Transgene SA has a net margin of -- compared to Adocia SA's net margin of --. Adocia SA's return on equity of -- beat Transgene SA's return on equity of -182.92%.
Company Gross Margin Earnings Per Share Invested Capital ADOCYAdocia SA-- -- -$1.3M TRGNFTransgene SA-- -- -$660.3K -
What do Analysts Say About ADOCY or TRGNF?
Adocia SA has a consensus price target of --, signalling downside risk potential of --. On the other hand Transgene SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Adocia SA has higher upside potential than Transgene SA, analysts believe Adocia SA is more attractive than Transgene SA.
Company Buy Ratings Hold Ratings Sell Ratings ADOCYAdocia SA0 0 0 TRGNFTransgene SA0 0 0 -
Is ADOCY or TRGNF More Risky?
Adocia SA has a beta of -0.180, which suggesting that the stock is 118.026% less volatile than S&P 500. In comparison Transgene SA has a beta of 45.447, suggesting its more volatile than the S&P 500 by 4444.7%.
-
Which is a Better Dividend Stock ADOCY or TRGNF?
Adocia SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Transgene SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Adocia SA pays -- of its earnings as a dividend. Transgene SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADOCY or TRGNF?
Adocia SA quarterly revenues are --, which are smaller than Transgene SA quarterly revenues of $105.2K. Adocia SA's net income of -- is lower than Transgene SA's net income of --. Notably, Adocia SA's price-to-earnings ratio is -- while Transgene SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Adocia SA is 17.36x versus 865.90x for Transgene SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADOCYAdocia SA17.36x -- -- -- TRGNFTransgene SA865.90x -- $105.2K --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
